New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy

Over the past three decades the lysosomal storage diseases have served as model for rare disease treatment development. While these efforts have led to considerable success, important challenges remain. For example, no treatments are currently approved for nearly two thirds of all lysosomal diseases...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuchman, Edward H., Ledesma, Maria D., Simonaro, Calogera M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992818/
https://www.ncbi.nlm.nih.gov/pubmed/33766102
http://dx.doi.org/10.1186/s13023-021-01779-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992818/
https://www.ncbi.nlm.nih.gov/pubmed/33766102
http://dx.doi.org/10.1186/s13023-021-01779-4

Ejemplares similares